"10.1371_journal.pone.0057631","plos one","2013-03-05T00:00:00Z","Brandy Young-Gqamana; Nastry Brignol; Hui-Hwa Chang; Richie Khanna; Rebecca Soska; Maria Fuller; Sheela A Sitaraman; Dominique P Germain; Roberto Giugliani; Derralynn A Hughes; Atul Mehta; Kathy Nicholls; Pol Boudes; David J Lockhart; Kenneth J Valenzano; Elfrida R Benjamin","University of Cape Town, Institute of Infectious Disease and Molecular Medicine, Division of Medical Biochemistry, Cape Town, South Africa; Amicus Therapeutics, Cranbury, New Jersey, United States of America; Lysosomal Diseases Research Unit, South Australia Pathology at Women’s and Children’s Hospital, Adelaide, South Australia, Australia; Division of Medical Genetics, University of Versailles – Saint Quentin en Yvelines, Hôpital Raymond Poincaré (Assistance Publique - Hôpitaux de Paris), Garches, France; Medical Genetics Service, Clinic Hospital of Porto Alegre Federal University of Rio Grande do Sul, Porto Alegre, Brazil; Lysosomal Storage Disorders Unit, Department of Academic Haematology, Royal Free Hospital and University College Medical School, London, United Kingdom; Department of Nephrology, Royal Melbourne Hospital, Parkville, Victoria, Australia","Revised manuscript critically for important intellectual content: ERB DJL KJV. Final approval of the version to be published: BY-G NB H-HC RK RS MF SAS DPG RG DAH AM KN PB DJL KJV ERB. Conceived and designed the experiments: BY-G NB RK PB DJL KJV ERB. Performed the experiments: BY-G NB H-HC RS MF SAS DPG RG DAH AM KN. Analyzed the data: BY-G NB MF SAS ERB. Contributed reagents/materials/analysis tools: BY-G NB MF SAS. Wrote the paper: BY-G NB ERB.","Brandy Young-Gqamana is a former employee of Amicus Therapeutics. Nastry Brignol, Hui-Hwa Chang, Richie Khanna, Rebecca Soska, Sheela A. Sitaraman, Pol Boudes, David J. Lockhart, Kenneth J. Valenzano, and Elfrida R. Benjamin are employed by Amicus Therapeutics and are shareholders in the company. Maria Fuller was a collaborator with Amicus Therapeutics. All other authors were investigators on the Phase 2 clinical studies of migalastat HCl. Dominique P. Germain has received research funding, consultancy fees, and travel expenses from Genzyme and Shire HGT. Roberto Giugliani is a consultant and investigator for Actelion, Amicus, BioMarin, Genzyme and Shire HGT. Derralynn A. Hughes is a consultant for Amicus, Shire HGT, Genzyme, Actelion, has been on a Speaker's Bureau for Amicus, Shire HGT, Genzyme, and Actelion, and has received grants from Amicus, Shire HGT, and Genzyme. Atul Mehta has received honoraria, research funding, consultancy fees, and travel expenses from Shire HGT, Genzyme, Actelion, Protalix, and Amicus. Kathy Nicholls has received travel and research support and speaker's honoraria from Amicus, Shire HGT and Genzyme. Amicus Therapeutics funded the research and any publication fees. The α-Gal A (Fabrazyme) used in this study is a product produced by Genzyme. Maria Fuller is employed by SA Pathology, Adelaide. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all of the PLOS ONE policies on sharing data and materials.","2013","03","Brandy Young-Gqamana","BYG",16,TRUE,7,11,5,3,TRUE,TRUE,FALSE,0,NA,FALSE
